{"organizations": [], "uuid": "90a0dbae5794f0c5aee4c3aa37b43fc09022b8c7", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-assembly-biosciences-presents-posi/brief-assembly-biosciences-presents-positive-interim-data-from-phase-1a-and-1b-studies-of-abi-h0731-in-hbv-patients-idUSFWN1RP06C", "country": "US", "domain_rank": 408, "title": "BRIEF-Assembly Biosciences Presents Positive Interim Data from Phase 1a and 1b Studies of ABI-H0731 in HBV Patients", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-12T10:35:00.000+03:00", "replies_count": 0, "uuid": "90a0dbae5794f0c5aee4c3aa37b43fc09022b8c7"}, "author": "", "url": "https://www.reuters.com/article/brief-assembly-biosciences-presents-posi/brief-assembly-biosciences-presents-positive-interim-data-from-phase-1a-and-1b-studies-of-abi-h0731-in-hbv-patients-idUSFWN1RP06C", "ord_in_thread": 0, "title": "BRIEF-Assembly Biosciences Presents Positive Interim Data from Phase 1a and 1b Studies of ABI-H0731 in HBV Patients", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "brief-assembly biosciences presents positive interim data", "sentiment": "negative"}, {"name": "assembly biosciences inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "hbv patients reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 12, 2018 / 7:35 AM / Updated 23 minutes ago BRIEF-Assembly Biosciences Presents Positive Interim Data from Phase 1a and 1b Studies of ABI-H0731 in HBV Patients Reuters Staff 1 Min Read \nApril 12 (Reuters) - Assembly Biosciences Inc: \n* ASSEMBLY BIOSCIENCES PRESENTS POSITIVE INTERIM DATA FROM PHASE 1A AND 1B STUDIES OF ABI-H0731 IN HBV PATIENTS IN A LATE-BREAKER SESSION AT THE EASL CONFERENCE \n* SAYS GENERALLY SAFE AND WELL TOLERATED; PLANNING UNDERWAY FOR PHASE 2A STUDIES BEGINNING SUMMER 2018 Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-04-12T10:35:00.000+03:00", "crawled": "2018-04-12T11:11:04.047+03:00", "highlightTitle": ""}